Literature DB >> 16150490

Pharmaceutical cost management and access to psychotropic drugs: the U.S. context.

Haiden A Huskamp1.   

Abstract

In recent years, prescription drug expenditures in the United States have increased rapidly. In 2003, spending on prescription medications totaled $179.2 billion dollars, or approximately 11% of national health expenditures [Smith, C., Cowan, C., Sensenig, A., Catlin, A., the Health Accounts Team. (2005). Health spending growth slows in 2003. Health Affairs, 24 (1) 185-194]. In response to rapid increases in prescription drug expenditures, both public and private payers of health care services have adopted strategies to try to contain drug costs, including drug formularies, prior authorization programs, cost sharing and utilization management. In this paper, I provide a background on prescription drug spending trends, financing, and access to medications; describe some of the tools used most commonly to manage prescription drug utilization; present results from the literature on the impact of these tools; and discuss some implications of this information for the new Medicare prescription drug benefit to be implemented in 2006 as well as for future prescription drug innovation.

Mesh:

Year:  2005        PMID: 16150490      PMCID: PMC1378114          DOI: 10.1016/j.ijlp.2005.08.004

Source DB:  PubMed          Journal:  Int J Law Psychiatry        ISSN: 0160-2527


  28 in total

1.  Prescription drug prices: why do some pay more than others do?

Authors:  R G Frank
Journal:  Health Aff (Millwood)       Date:  2001 Mar-Apr       Impact factor: 6.301

2.  Effect of a three-tier prescription copay on pharmaceutical and other medical utilization.

Authors:  B Motheral; K A Fairman
Journal:  Med Care       Date:  2001-12       Impact factor: 2.983

3.  Choosing a first-line antidepressant: equal on average does not mean equal for everyone.

Authors:  G Simon
Journal:  JAMA       Date:  2001-12-19       Impact factor: 56.272

4.  Effect of tiered prescription copayments on the use of preferred brand medications.

Authors:  Thomas S Rector; Michael D Finch; Patricia M Danzon; Mark V Pauly; Bharati S Manda
Journal:  Med Care       Date:  2003-03       Impact factor: 2.983

5.  Managing psychotropic drug costs: will formularies work?

Authors:  Haiden A Huskamp
Journal:  Health Aff (Millwood)       Date:  2003 Sep-Oct       Impact factor: 6.301

6.  Impact of Maine's Medicaid drug formulary change on non-Medicaid markets: spillover effects of a restrictive drug formulary.

Authors:  Y Richard Wang; Mark V Pauly; Y Aileen Lin
Journal:  Am J Manag Care       Date:  2003-10       Impact factor: 2.229

7.  Psychotropic practice patterns for youth: a 10-year perspective.

Authors:  Julie Magno Zito; Daniel J Safer; Susan DosReis; James F Gardner; Laurence Magder; Karen Soeken; Myde Boles; Frances Lynch; Mark A Riddle
Journal:  Arch Pediatr Adolesc Med       Date:  2003-01

8.  The effect of incentive-based formularies on prescription-drug utilization and spending.

Authors:  Haiden A Huskamp; Patricia A Deverka; Arnold M Epstein; Robert S Epstein; Kimberly A McGuigan; Richard G Frank
Journal:  N Engl J Med       Date:  2003-12-04       Impact factor: 91.245

9.  Specialty health care, treatment patterns, and quality: the impact of a mental health carve-out on care for depression.

Authors:  Susan H Busch
Journal:  Health Serv Res       Date:  2002-12       Impact factor: 3.402

10.  Employer drug benefit plans and spending on prescription drugs.

Authors:  Geoffrey F Joyce; José J Escarce; Matthew D Solomon; Dana P Goldman
Journal:  JAMA       Date:  2002-10-09       Impact factor: 56.272

View more
  9 in total

1.  Medicaid cost control measures aimed at second-generation antipsychotics led to less use of all antipsychotics.

Authors:  William B Vogt; Geoffrey Joyce; Jing Xia; Riad Dirani; George Wan; Dana P Goldman
Journal:  Health Aff (Millwood)       Date:  2011-12       Impact factor: 6.301

2.  Trends in the access to and the use of antipsychotic medications and psychotropic co-treatments in Asian patients with schizophrenia.

Authors:  Y-T Xiang; G S Ungvari; C U Correll; H F K Chiu; N Shinfuku
Journal:  Epidemiol Psychiatr Sci       Date:  2015-08-20       Impact factor: 6.892

Review 3.  Impact of pharmaceutical prior authorisation policies : a systematic review of the literature.

Authors:  Jaume Puig-Junoy; Iván Moreno-Torres
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

4.  National trends in second-generation antipsychotic augmentation for nonpsychotic depression.

Authors:  Tobias Gerhard; Ayse Akincigil; Christoph U Correll; Neil J Foglio; Stephen Crystal; Mark Olfson
Journal:  J Clin Psychiatry       Date:  2014-05       Impact factor: 4.384

5.  The relationship of antidepressant prescribing concentration to treatment duration and cost.

Authors:  Dominic Hodgkin; Elizabeth L Merrick; Deirdre Hiatt
Journal:  J Ment Health Policy Econ       Date:  2012-03

6.  Management of newer medications for attention-deficit/hyperactivity disorder in commercial health plans.

Authors:  Dominic Hodgkin; Constance M Horgan; Amity E Quinn; Elizabeth L Merrick; Maureen T Stewart; Laurel K Leslie
Journal:  Clin Ther       Date:  2014-11-14       Impact factor: 3.393

7.  Does private insurance adequately protect families of children with mental health disorders?

Authors:  Susan H Busch; Colleen L Barry
Journal:  Pediatrics       Date:  2009-12       Impact factor: 7.124

8.  Benefit limits for behavioral health care in private health plans.

Authors:  Dominic Hodgkin; Constance M Horgan; Deborah W Garnick; Elizabeth L Merrick
Journal:  Adm Policy Ment Health       Date:  2008-11-27

9.  Factors Associated With Off-Label Utilization of Second-Generation Antipsychotics Among Publicly Insured Adults.

Authors:  Marcela Horvitz-Lennon; Rita Volya; Simon Hollands; Katya Zelevinsky; Andrew Mulcahy; Julie M Donohue; Sharon-Lise T Normand
Journal:  Psychiatr Serv       Date:  2021-06-02       Impact factor: 4.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.